Glycotope’s Competitors, Revenue, Number of Employees, Funding, Acquisitions & News

Glycotope engages in drug development, analytics, glycobiology and cell biology to develop pharmaceutical therapeutics and nutrition additives. Read more

12 Followers on Owler
12 Followers on Owler
12 Followers on Owler
12 Followers on Owler

Glycotope engages in drug development, analytics, glycobiology and cell biology to develop pharmaceutical therapeutics and nutrition additives. Read more

Henner Kollenberg's photo - Managing Director of Glycotope

Managing Director

Henner Kollenberg

CEO Approval Rating

90/100

Founded:

2000

Status:

PrivateIndependent Company

Est. Annual Revenue
Est. Employees

TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

Biovian is seen as one of Glycotope's biggest rivals. Biovian was founded in 2003 in Turku, Southern Finland. Like Glycotope, Biovian also operates in the Biotechnology sector. Biovian generates $4.6M less revenue than Glycotope.

Biomeva is one of Glycotope's top competitors. Biomeva was founded in 1993, and its headquarters is in Heidelberg, Baden-Württemberg. Biomeva operates in the industry. Biomeva has 97 fewer employees than Glycotope.

3P Biopharmaceuticals is one of Glycotope's top rivals. 3P Biopharmaceuticals was founded in 2006, and is headquartered in Noain, Navarra. Like Glycotope, 3P Biopharmaceuticals also works within the Biotechnology sector. 3P Biopharmaceuticals generates $3M more revenue vs. Glycotope.

Weigh-in!

Help the Owler community know more

Growth Score - 1/1

Is $11M a good estimate for Glycotope's revenue?

Acquisitions

No recent acquisitions found related to Glycotope

Glycotope Funding History

$76.4M$166.4M

Since Glycotope was founded in 2000, it has participated in 2 rounds of funding. In total Glycotope has raised $166.4M. Glycotope's last funding round was on Oct 2015 for a total of $90.0M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Equity
Oct 2015
$90M

Octapharma AG

Unattributed
Mar 2014
$76.4M
-

Since Glycotope was founded in 2000, it has participated in 2 rounds of funding. In total Glycotope has raised $166.4M. Glycotope's last funding round was on Oct 2015 for a total of $90.0M

Investments

No recent investments found related to Glycotope

Glycotope News

November 28, 2018BioPortfolio

Glycotope GmbH Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 13112018 Prices from USD $250

SummaryGlycotope GmbH Glycotope is a clinical stage immunooncology company that develops glycobiology... See more »
August 26, 2018BioPortfolio

Glycotope GmbH Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 17042018 Prices from USD $250

SummaryGlycotope GmbH Glycotope is a clinical stage immunooncology company that develops glycobiology... See more »
August 10, 2018BioPortfolio

Glycotope GmbH Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 11072018 Prices from USD $250

SummaryGlycotope GmbH Glycotope is a clinical stage immunooncology company that develops glycobiology... See more »
August 3, 2018BioPharma-Reporter

Daiichi Sankyo and Glycotope reach agreement for "first-in-class" ADC

Daiichi Sankyo and Glycotope have signed a licensing agreement to develop an antibody-drug conjugate ... See more »
July 18, 20184-traders

DCprime and Glycotope announce licensing agreement and collaboration

(4-traders.com) LEIDEN, THE NETHERLANDS, AND BERLIN, GERMANY / ACCESSWIRE / July 18, 2018 / DCprime B... See more »
April 16, 2018Enterprise Innovation

Glycotope selects preclinical development partner to advance immunotherapeutic pipeline

Glycotype GmbH, an immuno-oncological products developer, has selected Crown Bioscience, a wholly-own... See more »
March 28, 2018The Korea Bizwire

Glycotope Selects CrownBio as a Preclinical Development Partner to Advance Their Immunotherapeutic Pipeline

SAN DIEGO, Mar. 28 (Korea Bizwire) - Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience ... See more »

Glycotope Press Releases

October 8, 2015BUSINESS WIRE

Octapharma AG Invests €80 Million to Acquire an Exclusive Worldwide License to Certain IP of Glycotope's Recombinant Technology and to Become a Minority Shareholder of Glycotope GmbH Berlin

LACHEN, Switzerland--(BUSINESS WIRE)--Octapharma invests €80m to acquire exclusive worldwide license ... See more »
August 10, 2015PR-INSIDE.COM

Glycotope GmbH - Product Pipeline Review - 2015

(PR-inside.com) Global Markets Direct's, 'Glycotope GmbH - Product Pipeline Review - 2015', provides ... See more »
April 22, 2015PRSYNC

Glycotope GmbH - Product Pipeline Review - 2014

Glycotope GmbH - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Glycotope GmbH - Pr... See more »

Social Media

Headquarters

Robert-Roessle-Str. 10

Berlin, Berlin13125

49-30-9489-2600

Driving Directions »

Trending Companies

Summary

ABOUT

Overview

Glycotope engages in drug development, analytics, glycobiology and cell biology to develop pharmaceutical therapeutics and nutrition additives. Glycotope was founded in 2000. Glycotope's headquarters is located in Berlin, Berlin, DE 13125. It has rais...

CEO

Glycotope's Managing Director, Henner Kollenberg, currently has an approval rating of 90%. Glycotope's primary competitors are Biovian, Biomeva & 3P Biopharmaceuticals.

Website

glycotope.com

Frequently Asked Questions about Glycotope

  1. When was Glycotope founded?

    Glycotope was founded in 2000
  2. Who is Glycotope's CEO?

    Glycotope's CEO is Henner Kollenberg
  3. How much revenue does Glycotope generate?

    Glycotope generates $11M in revenue
  4. How much funding does Glycotope have?

    Glycotope has historically raised $166.4M in funding
  1. Where is Glycotope's headquarters?

    Glycotope's headquarters is in Berlin Berlin, DE
  2. How many employees does Glycotope have?

    Glycotope has 180 employees
  3. What sector does Glycotope operate in?

    Glycotope is in Biotechnology
  4. Who are Glycotope's competitors?

    Glycotope's top competitors are Biovian, Biomeva, 3P Biopharmaceuticals